Dongyang Guangyao said its insulin glargine injection, appro
文 / 小金
2026-10-27 14:20:03
来源:亚金网
Dongyang Guangyao said its insulin glargine injection, approved by the U.S. FDA in April, began U.S. commercial shipments in July with an initial batch of 1.152 mln units. The company has locked more than 18 mln units in overseas orders; the product is the first Chinese insulin to enter the U.S. market.
